机译:Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
Translational Immunology Program, Benaroya Research Institute, Seattle, WA, United States;
Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, NY, United States;
Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, UnitedSanford Research, University of South Dakota, Sioux Falls, SD, United StatesTolerance Assays and Data Analysis Group, Immune Tolerance Network, Bethesda, MD, United StatesClinical Trials Group, Immune Tolerance Network, San Francisco, CA, United StatesDiabetes Program, Benaroya Research Institute, Seattle, WA, United StatesRho Federal Systems Division, Inc., Chapel Hill, NC, United StatesDivision of Allergy, Immunology, and Transplantation, National Institute of Allergy and InfectiousDiabetes Center and Department of Medicine, University of California San Francisco, San Francisco;